Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

I haven’t been too happy with my blood work with CLL, but I try to enjoy what I can — including apples during fall.

Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...

One year, after breast cancer treatment, I decided to have a Christmas photoshoot with my family, which turned out to be a good laugh in the end.

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

In an interview with CURE ®, Maggie Bushway reflected on rediscovering her childhood writings and her father's blog posts ...